Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by inforthelongoneon Aug 05, 2016 1:45pm
197 Views
Post# 25114738

RE:LP's by patient count

RE:LP's by patient countPatient counts really do not matter as much as you would think.  The patients swing back and forth. Patients try a LP, find they don't like the product and then try another.  And generally, patients have to renew their status/script on a 1-3 month basis, at which point they will tend to try another LP to see what their product is like.
The real story is on the pending rec user - this and many other MJ stocks will experience a lift between now and when the dust settles after legislation in Canada and potentially abroad - ie: Brazil, Germany and Austrialia - which CGC has interests in each of these markets. 
Dont' get me wrong, at the moment, CGC is dependant upon their subscriber base, but they are looking ahead too whereby their subscriber base will account for a very small percentage of their overall revenue.  CGC is well positioned to be a leader in this space and are making moves to be the dominant player, but many others are also in the same head space. 
The real story in the immediate future will be the Aug 24 ruling, but there will be hills ad valleys along the eway, this is at least a 10-18 month play that will really sow what this industry is all about.  Till then we ride the wave and the wave keeps getting bigger and bigger.  
Bullboard Posts